Lasa Supergenerics Limited (LASA) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE670X01014
Key metrics
- Market Cap
- ₹34 Cr
- P/E Ratio
- —
- EPS
- -3.29
- Book Value
- 9.9
- P/B Ratio
- 0.7
- ROE
- -68.7%
- ROCE
- -22.54%
- Debt / Equity
- 0.2
- Net Margin
- -135.6%
- Revenue Growth
- -82.35%
- Profit Growth
- -131.01%
- Dividend Yield
- —
- 52W High
- ₹14.08
- 52W Low
- ₹5.67
- Market Cap Band
- micro cap
- Face Value
- —
Ratios computed from the annual results period ending 2026-03-31.
About Lasa Supergenerics Limited
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
- Headquarters
- Ratnagiri, India
- Promoter Holding
- 54.65%
The full Lasa Supergenerics Limited analysis
Create a free account to open the complete LASA deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.